Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1977 1
1978 2
1980 2
1981 2
1983 1
1984 3
1985 2
1986 2
1987 3
1988 7
1989 7
1990 12
1991 7
1992 2
1993 1
1994 7
1995 1
1998 2
1999 2
2000 2
2001 5
2002 3
2003 11
2004 36
2005 33
2006 27
2007 37
2008 25
2009 20
2010 15
2011 15
2012 6
2013 3
2014 6
2015 8
2016 2
2017 4
2018 3
2019 13
2020 16
2021 7
2022 10
2023 9
2024 9
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

383 results

Results by year

Filters applied: . Clear all
Page 1
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK. Moreau P, et al. Among authors: lazzaro a. Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1. Lancet Oncol. 2018. PMID: 29866475 Clinical Trial.
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.
De Novellis D, Derudas D, Vincelli D, Fontana R, Della Pepa R, Palmieri S, Accardi F, Rotondo F, Morelli E, Gigliotta E, Roccotelli D, Marano L, Barone ML, Cetani G, Esposito D, Lazzaro A, Delle Cave G, Serio B, Morini D, Porrazzo M, Urciuoli E, Masucci C, Fanelli F, Rizzo M, Arcamone M, Trastulli F, Rocco S, Leone A, Bianco R, Salvatore F, Idato A, Sicari M, Tosi P, Rascato MG, Di Perna M, Falcone AP, Morello L, Carlisi M, Svanera G, Annunziata M, Frigeri F, Califano C, Carella AM, Marcacci G, Pane F, Risitano AM, Giudice V, Botta C, Selleri C. De Novellis D, et al. Among authors: lazzaro a. Eur J Haematol. 2025 Jan;114(1):105-114. doi: 10.1111/ejh.14314. Epub 2024 Oct 6. Eur J Haematol. 2025. PMID: 39370303 Free PMC article.
Diagnosis and Management of Parathyroid Carcinoma.
Lazzaro A, Zhao GQ, Kulke M. Lazzaro A, et al. Clin Pharmacol Ther. 2024 Dec;116(6):1496-1505. doi: 10.1002/cpt.3432. Epub 2024 Sep 5. Clin Pharmacol Ther. 2024. PMID: 39234888 Review.
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R, Mateos MV, Richardson PG, Sonneveld P; OCEAN (OP-103) Investigators. Schjesvold FH, et al. Among authors: lazzaro a. Lancet Haematol. 2022 Feb;9(2):e98-e110. doi: 10.1016/S2352-3026(21)00381-1. Epub 2022 Jan 12. Lancet Haematol. 2022. PMID: 35032434 Clinical Trial.
Efficacy, safety, and anti-inflammatory properties of the switch to a doravirine-based regimen among antiretroviral-experienced elderly people living with HIV-1: the DORAGE cohort.
Lazzaro A, Recchia GE, Alessi F, Santinelli L, Battistini L, Morcos J, Romano F, Bugani G, Maddaloni L, Caruso S, D'Amico M, Mezzaroma I, Falciano M, Fimiani C, Sfara G, Leone MG, Turriziani O, Mastroianni CM, d'Ettorre G. Lazzaro A, et al. Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0081524. doi: 10.1128/aac.00815-24. Epub 2025 Feb 18. Antimicrob Agents Chemother. 2025. PMID: 39964162 Free PMC article.
Could SP-A and SP-D Serum Levels Predict COVID-19 Severity?
Maddaloni L, Zullino V, Bugani G, Lazzaro A, Brisciani M, Mastroianni CM, Santinelli L, Ruberto F. Maddaloni L, et al. Among authors: lazzaro a. Int J Mol Sci. 2024 May 22;25(11):5620. doi: 10.3390/ijms25115620. Int J Mol Sci. 2024. PMID: 38891806 Free PMC article.
383 results